|
Mr. Leufkens was one of the founders and Vice-President of Business Development of AM-Pharma B.V., a biopharmaceutical company focused on clinical development of novel drugs in the field of severe infectious and inflammatory diseases. AM-Pharma�s peptide technology was a spin out of Pharming Group N.V. (Euronext:PHARM.AS), where Mr. Leufkens held senior positions in both product and business development. After playing a key role in the clinical development of transgenic human Lactoferrin at Pharming Group N.V., Mr. Leufkens took the initiative to commercialize small antimicrobial peptides derived from this large protein as novel antibiotics, leading to the spin-out of AM-Pharma B.V. Prior to AM-Pharma, Mr. Leufkens held positions in regulatory affairs, clinical development and project management with various European companies, including Astellas Europe, a wholly owned subsidiary of Astellas Pharma Inc., a public company traded on the Tokyo Stock Exchange (then Yamanouchi Europe). While at Yamanouchi Europe, Mr. Leufkens headed the project team responsible for the clinical development of Omnic� (Tamsulosin) for benign prostatic hyperplasia in Europe. Mr. Leufkens holds M.Sc. and Pharm. D. degrees from Utrecht University and an MBA from Bradford University (UK). | 